NCT05939167RecruitingPhase 1/2
Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
A Double-blind, Randomized Placebo-controlled Clinical Trial to Investigate the Safety and Efficacy of Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
Source: ClinicalTrials.gov · Last updated 12 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 15 May 2023
- Start date
- 10 Dec 2023
- Primary completion date
- 10 Jul 2027
- Lead sponsor
- Cell Energy Life Sciences Group Co. LTD
- Diseases
- HIV
- NCT number
- NCT05939167
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 150
- From 10 Dec 2023 to the primary completion date, 10 Jul 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- received treatment of hormones or other immunosuppressive drugs for a long time.
- received immunosuppressive drugs or systemic cytotoxic drugs for more than 3 months before recruiting
- drug addiction within 6 months, or the urine drug test is positive
Other illness
- have HBV/HCV/HDV/HEV infection, and the virological test is positive.
- have HIV-2 infection.
- have serious complications in organs including renal, circulatory, respiratory, digestive, endocrine, neural and immunological diseases and tumors.
Other
- The viral load for CMV and EBV is more than 1000 copies/ML.
- with serious AIDS related or unrelated events.
- have poor compliance during treatment.
- participate in other clinical trials currently
- pregnant, breastfeeding, or have fertility requirements.
- unable or unwilling to provide informed consents, or unable to comply with research requirements.
- Other serious situations that may hinder clinical trials.
Who the study is looking for
- Confirmed HIV infection, aged 18-65, both genders
- CD4+T count less than 500 cells/ul at baseline.
- No serious AIDS related events. 3. could understand and sign the informed consent form and comply with the requirements of this study.
- 4\. agree not to participate in other studies and not to receive other immunotherapies during the period of participation in this study
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing 302 Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Beijing YouAn Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Shenzhen Third People's Hospital Coordinator of this site? Confirm its status | Shenzhen | China | Recruiting |
| The Fifth Hospital of Shijiazhuang Coordinator of this site? Confirm its status | Shijiazhuang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.